Application of GLX351322 in preparation of medicine for preventing and treating hemorrhagic stroke and medicine thereof

By inhibiting NOX4 enzyme activity and blocking the ISR-eIF2α-ATF4-NOX4-ROS cycle through GLX351322, combined with other drugs, the problem of lack of effective drugs for hemorrhagic stroke has been solved, achieving significant reduction in hemorrhage volume and neuroprotective effects. It is suitable for hemorrhagic stroke and other neurodegenerative diseases.

CN120899714APending Publication Date: 2025-11-07SUZHOU UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511195774.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-26
Publication Date
2025-11-07

AI Technical Summary

Technical Problem

Currently, there are no effective drugs to prevent or treat hemorrhagic stroke and improve patients' functional impairment. Existing technologies mainly involve surgical removal of hematomas and reduction of intracranial pressure, but lack drug treatment options.

Method used

GLX351322 was used as an inhibitor of NADPH oxidase 4 (NOX4) and was administered orally or intravenously to inhibit NOX4 enzyme activity, block the ISR-eIF2α-ATF4-NOX4-ROS cycle, reduce oxidative stress and inflammatory response, and was combined with other drugs such as nicotinamide nucleoside (NR), reduced nicotinamide adenine dinucleotide phosphate (NADPH), PERK kinase inhibitors for synergistic treatment.

Benefits of technology

It significantly reduces hemorrhage volume by 20-30%, provides neuroprotection, reduces oxidative stress and inflammation, improves neurological function, has low toxicity, is suitable for hemorrhagic stroke, and may have therapeutic effects on other neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

According to the application of the GLX351322 in preparation of the medicine for preventing and treating the hemorrhagic stroke, the molecular formula of the GLX351322 is C21H25N3O5S, the CAS number of the GLX351322 is 835598-94-2, and the molecular weight of the GLX351322 is 431.51. The administration amount of the GLX351322 is 1-5 mg / kg / d, and the administration mode comprises oral administration, intravenous injection or intravenous drip. According to the application disclosed by the invention, the GLX351322 is injected into a mouse ICH model for treatment, so that the volume of cerebral hematoma of a mouse can be remarkably reduced, oxidative stress and inflammatory response can be inhibited, and ISR-eIF2alpha-ATF4-NOX4-ROS circulation can be blocked, and the GLX351322 is prompted to have a certain prevention and treatment effect on hemorrhagic cerebral apoplexy.
Need to check novelty before this filing date? Find Prior Art